India Pharma Outlook Team | Wednesday, 13 May 2026
Patients with Heart Failure and CKD often face serious complications beyond their primary disease. One growing concern is hyperkalaemia, a condition that raises potassium levels in the blood.
Doctors now view hyperkalaemia as a recurring clinical challenge instead of a temporary laboratory abnormality. The condition frequently disrupts treatment continuity for patients managing chronic kidney disease and heart failure.
To address this challenge, AstraZeneca Pharma India launched K+ Connect, a pan-India multidisciplinary initiative. The program focuses on improving hyperkalaemia management through stronger clinical coordination and standardized treatment practices. AstraZeneca aims to help doctors identify risks earlier and improve long-term patient outcomes.
Hyperkalaemia affects a small percentage of the general population. However, the condition appears far more frequently among patients with chronic kidney disease. Experts estimate that nearly 40–50% of CKD patients experience hyperkalaemia, especially during advanced disease stages. India also faces a growing burden, with chronic hyperkalaemia prevalence estimated at 13.24%.
Doctors say hyperkalaemia often forces changes in important medications used for heart failure treatment. Many patients stop or reduce guideline-directed medical therapy because potassium levels become difficult to control. These interruptions may increase hospitalization risks and worsen long-term health outcomes.
Also Read: Role of Optical Imaging in Early Cancer Detection and Treatment
K+ Connect plans to bring together multidisciplinary experts from 33 leading healthcare centres across India. The initiative will support more structured hyperkalaemia management and encourage stronger coordination across specialties. The participating teams include experts from cardiology, nephrology, internal medicine, emergency medicine, nursing, and pharmacy.
Dr Sandeep Arora, Director, Medical Affairs, AstraZeneca Pharma India, said hyperkalaemia remains an under-recognized risk in chronic disease management. He added that doctors often make reactive treatment decisions instead of proactive long-term care plans. According to him, K+ Connect aims to improve clinical alignment and support evidence-based management approaches.
The initiative will roll out in two phases across participating institutions. The first phase will focus on clinician education and multidisciplinary alignment. Doctors and healthcare teams will discuss recurrence risks, treatment continuity, and monitoring strategies.
The second phase will include case-based workshops and institutional discussions. These workshops will help hospitals create consensus-driven treatment pathways for hyperkalaemia management. The pathways will cover screening protocols, treatment thresholds, monitoring timelines, and escalation criteria.
Several major hospitals joined the national network supporting the initiative. These hospitals include Max Healthcare, Jaslok Hospital, Apollo Hospitals, and Yashoda Hospital. Another 29 tertiary care centres also joined the collaboration.
Healthcare experts believe multidisciplinary coordination can improve consistency in patient care. They also expect structured pathways to reduce treatment gaps across hospitals and specialties.
Many patients fail to recognize hyperkalaemia during early stages. The condition may not show clear symptoms until potassium levels become dangerously high. Severe cases can trigger irregular heart rhythms, muscle weakness, and cardiac complications.
Doctors also point to fragmented care systems as a major challenge. Patients with heart failure and CKD often consult multiple specialists during treatment. Poor coordination between departments may delay timely interventions and monitoring.
Experts believe regular screening and standardized monitoring can improve long-term disease management. Better coordination may also help patients continue important therapies without unnecessary interruptions.
Following the consensus protocol publication, participating hospitals may receive Centre of Excellence status. Institutions will qualify based on pathway adoption, staff training, and continuous improvement practices.
The initiative also reflects a broader shift in chronic disease management across India. Pharmaceutical companies increasingly support scientific exchange and healthcare collaborations beyond medicines alone. AstraZeneca stated that participating hospitals will continue governing all clinical decisions and protocol adoption.
Healthcare experts expect programs like K+ Connect to strengthen multidisciplinary care models nationwide. They also believe structured hyperkalaemia management can improve outcomes for patients living with heart failure and CKD.
AstraZeneca Pharma India Ltd. develops and commercializes medicines across several therapeutic deals in India. The company focuses on oncology, cardiovascular diseases, renal care, respiratory diseases, and rare conditions.
Headquartered in Bengaluru, AstraZeneca Pharma India also supports clinical research and healthcare collaborations nationwide. The company continues expanding its presence in cardio-renal care through scientific and patient-focused initiatives.
.jpg)
.jpg)
